TOP > 外国特許検索 > METHOD FOR DETERMINING DEPRESSION, KIT FOR ANALYZING SEROTONIN TRANSPORTER, AND KIT FOR ANALYZING UBIQUITINATED SEROTONIN TRANSPORTER IN BLOOD

METHOD FOR DETERMINING DEPRESSION, KIT FOR ANALYZING SEROTONIN TRANSPORTER, AND KIT FOR ANALYZING UBIQUITINATED SEROTONIN TRANSPORTER IN BLOOD

外国特許コード F130007583
整理番号 S2013-0359-N0
掲載日 2013年7月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2012JP068348
国際公開番号 WO 2013012038
国際出願日 平成24年7月19日(2012.7.19)
国際公開日 平成25年1月24日(2013.1.24)
優先権データ
  • 特願2011-160052 (2011.7.21) JP
  • 特願2011-228055 (2011.10.17) JP
発明の名称 (英語) METHOD FOR DETERMINING DEPRESSION, KIT FOR ANALYZING SEROTONIN TRANSPORTER, AND KIT FOR ANALYZING UBIQUITINATED SEROTONIN TRANSPORTER IN BLOOD
発明の概要(英語) [Problem] To provide: a method for utilizing a novel marker, including a method for determining depression; and a kit for analyzing an ubiquitinated serotonin transporter.
[Solution] A method for determining depression, comprising a step of analyzing the proportion of an ubiquitinated serotonin transporter in a blood sample collected from a subject; and a kit for analyzing an ubiquitinated serotonin transporter in blood, which comprises an ubiquitinated protein collector material and an anti-serotonin transporter antibody and is used for the analysis of the proportion of an ubiquitinated serotonin transporter in a collected blood sample.
従来技術、競合技術の概要(英語) BACKGROUND ART
Is a depression, the diagnosis of mental disorders American American, statistical Manual (Diagnostic and Statistical Manual of Mental Disorders: DSM-4) in the plate 4, such as chronic depression, interest, the loss of pleasure, significant changes in body weight, insomnia or excessive, the loss of the electric force, the impatience of the psychomotor or still, the sense of no value, guilt, thinking force, loss of concentration, such as suicidal symptoms of disease.
In the condition of depression, serotonin, noradrenaline and, monoamine neurotransmitter dopamine is involved in the degradation of the proposed hypothesis. For serotonin, the pre-synaptic nerve endings in healthy individuals from the synaptic cleft is released and a sufficient amount of serotonin, a serotonin receptor present in the post-synaptic nerve endings by accommodating a serotonin signaling is performed, the serotonin excess of serotonin in the synaptic cleft is removed, the pre-synaptic nerve endings to re-release of serotonin from the synaptic cleft. On the other hand, in patients with depression of the pre-synaptic serotonin release from the nerve endings is insufficient, the post-synaptic nerve endings deemed to be unable to receive sufficient serotonin. That is, in patients with depression due to a shortage of serotonin in the synaptic cleft is considered.
On the assumption that the hypothesis of the monoamine, serotonin was used as an indicator of depression (SSRI) such as sertraline diagnosis of a selective serotonin reuptake inhibitor antidepressant agent is an effective ingredient.
Serotonin in the expression of the central nervous system and is associated with platelet and leukocyte expression has been reported. White blood cells containing lymphocytes and platelets to central serotonin in many respects to the serotonin transporter serotonin nerve has the property to be common, platelets and lymphocytes obtained from peripheral blood leukocytes including as biological markers of depression have been made in research applications. In addition, a platelet serotonin absorption is performed in the serotonin neurons on the serotonin system and expresses a gene sequence is the same as that of a report. Furthermore, the changes in the expression of the serotonin and, in the central nervous system function and seasonal affective disorder such as psychiatric condition has been reported to be associated with. However, associated with the support mechanism is not yet clear.
In addition, treating depression associated with serotonin antidepressants many create an animal models of depression has been proposed. These depression-like behavior in the aspect shown in the model animal, administration of serotonin from the synaptic cleft and serotonin reuptake inhibition of the embodiments of the invention will not indicate that a depression-like behavior. Therefore, the antidepressant agent for performing screening of a candidate agent to the animal models of depression are utilized.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • MEIJO UNIVERSITY
  • 発明者(英語)
  • NABESHIMA Toshitaka
  • MOURI Akihiro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close